Oui, les antioxydants peuvent réduire le stress oxydatif associé à KEAP1.
AntioxydantsStress oxydatifTraitement
#3
Y a-t-il des essais cliniques pour KEAP1 ?
Des essais cliniques évaluent des traitements ciblant les anomalies de KEAP1.
Essais cliniquesTraitementsAnomalies génétiques
#4
Les thérapies ciblées sont-elles efficaces ?
Elles montrent un potentiel dans le traitement des cancers liés à KEAP1.
Thérapies cibléesCancerEfficacité
#5
Quels médicaments sont utilisés pour KEAP1 ?
Des inhibiteurs de la voie de signalisation de KEAP1 sont en cours d'étude.
MédicamentsInhibiteursVoies de signalisation
Complications
5
#1
Quelles complications sont liées à KEAP1 ?
Des complications incluent le cancer, les maladies respiratoires et l'inflammation chronique.
ComplicationsCancerMaladies respiratoires
#2
KEAP1 est-il lié à des maladies auto-immunes ?
Oui, des anomalies de KEAP1 peuvent contribuer à des maladies auto-immunes.
Maladies auto-immunesAnomaliesKEAP1
#3
Les maladies cardiovasculaires sont-elles associées à KEAP1 ?
Des études suggèrent un lien entre KEAP1 et les maladies cardiovasculaires.
Maladies cardiovasculairesLiaisonKEAP1
#4
Y a-t-il des risques de cancer avec KEAP1 ?
Oui, des mutations de KEAP1 sont souvent associées à un risque accru de cancer.
Risque de cancerMutationsKEAP1
#5
Les complications sont-elles réversibles ?
Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles.
ComplicationsGestionRéversibilité
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour KEAP1 ?
Les facteurs incluent le tabagisme, l'exposition aux toxines et des antécédents familiaux.
Facteurs de risqueTabagismeAntécédents familiaux
#2
L'âge influence-t-il KEAP1 ?
Oui, le risque de dysfonction de KEAP1 augmente avec l'âge.
ÂgeRisqueDysfonction
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies respiratoires ou de cancer augmentent le risque.
Antécédents médicauxRisqueMaladies
#4
L'environnement affecte-t-il KEAP1 ?
Oui, l'exposition à des polluants environnementaux peut altérer KEAP1.
EnvironnementPolluantsKEAP1
#5
Le stress oxydatif est-il un facteur de risque ?
Oui, un stress oxydatif accru peut contribuer à des anomalies de KEAP1.
Stress oxydatifFacteurs de risqueAnomalies
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine-1 de type kelch associée à ECH : Questions médicales les plus fréquentes",
"headline": "Protéine-1 de type kelch associée à ECH : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine-1 de type kelch associée à ECH : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-29",
"dateModified": "2026-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine-1 de type kelch associée à ECH"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines adaptatrices de la transduction du signal",
"url": "https://questionsmedicales.fr/mesh/D048868",
"about": {
"@type": "MedicalCondition",
"name": "Protéines adaptatrices de la transduction du signal",
"code": {
"@type": "MedicalCode",
"code": "D048868",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.024"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine-1 de type kelch associée à ECH",
"alternateName": "Kelch-Like ECH-Associated Protein 1",
"code": {
"@type": "MedicalCode",
"code": "D000072019",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Caleigh Mandel-Brehm",
"url": "https://questionsmedicales.fr/author/Caleigh%20Mandel-Brehm",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Divyanshu Dubey",
"url": "https://questionsmedicales.fr/author/Divyanshu%20Dubey",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Joseph L DeRisi",
"url": "https://questionsmedicales.fr/author/Joseph%20L%20DeRisi",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Michael R Wilson",
"url": "https://questionsmedicales.fr/author/Michael%20R%20Wilson",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Jing Zhao",
"url": "https://questionsmedicales.fr/author/Jing%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37441735",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jmedchem.3c00712"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nuclear Factor Erythroid 2-Related Factor 2/Kelch-Like ECH-Associated Protein 1 as a Predictor of Prognosis and Radiotherapy Resistance in Patients With Locally Advanced Rectal Cancer: A Prospective Analysis.",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37401495",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3346/jkms.2023.38.e200"
}
},
{
"@type": "ScholarlyArticle",
"name": "Structure-Based Identification of Kelch-like ECH-Associated Protein 1 as a Pharmacological Target of Electrophile-Containing Catechol-",
"datePublished": "2024-02-13",
"url": "https://questionsmedicales.fr/article/38481699",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsptsci.3c00281"
}
},
{
"@type": "ScholarlyArticle",
"name": "Homocysteine-potentiated Kelch-like ECH-associated protein 1 promotes senescence of neuroblastoma 2a cells via inhibiting ubiquitination of β-catenin.",
"datePublished": "2024-03-19",
"url": "https://questionsmedicales.fr/article/38501537",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ejn.16318"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chrysophanol ameliorates oxidative stress and pyroptosis in mice with diabetic nephropathy through the Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway.",
"datePublished": "2023-11-29",
"url": "https://questionsmedicales.fr/article/38019504",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18388/abp.2020_6778"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines adaptatrices de la transduction du signal",
"item": "https://questionsmedicales.fr/mesh/D048868"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéine-1 de type kelch associée à ECH",
"item": "https://questionsmedicales.fr/mesh/D000072019"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine-1 de type kelch associée à ECH - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine-1 de type kelch associée à ECH",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine-1 de type kelch associée à ECH",
"description": "Comment diagnostiquer une anomalie de KEAP1 ?\nQuels examens sont utilisés pour évaluer KEAP1 ?\nLes biopsies sont-elles nécessaires pour KEAP1 ?\nQuels marqueurs sont associés à KEAP1 ?\nY a-t-il des tests spécifiques pour KEAP1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine-1 de type kelch associée à ECH",
"description": "Quels symptômes sont liés à une dysfonction de KEAP1 ?\nLa dysfonction de KEAP1 cause-t-elle des maladies ?\nQuels signes cliniques sont observés ?\nLes symptômes varient-ils selon les individus ?\nY a-t-il des symptômes spécifiques au cancer lié à KEAP1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine-1 de type kelch associée à ECH",
"description": "Peut-on prévenir les anomalies de KEAP1 ?\nL'alimentation influence-t-elle KEAP1 ?\nLe tabagisme affecte-t-il KEAP1 ?\nL'exercice physique aide-t-il KEAP1 ?\nY a-t-il des recommandations pour KEAP1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine-1 de type kelch associée à ECH",
"description": "Quels traitements ciblent KEAP1 ?\nLes antioxydants aident-ils avec KEAP1 ?\nY a-t-il des essais cliniques pour KEAP1 ?\nLes thérapies ciblées sont-elles efficaces ?\nQuels médicaments sont utilisés pour KEAP1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine-1 de type kelch associée à ECH",
"description": "Quelles complications sont liées à KEAP1 ?\nKEAP1 est-il lié à des maladies auto-immunes ?\nLes maladies cardiovasculaires sont-elles associées à KEAP1 ?\nY a-t-il des risques de cancer avec KEAP1 ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine-1 de type kelch associée à ECH",
"description": "Quels sont les facteurs de risque pour KEAP1 ?\nL'âge influence-t-il KEAP1 ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement affecte-t-il KEAP1 ?\nLe stress oxydatif est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072019#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de KEAP1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent identifier des mutations de KEAP1."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer KEAP1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'électrophorèse des protéines et les tests de fonction hépatique sont courants."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour KEAP1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être réalisée pour évaluer les tissus affectés par des mutations de KEAP1."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à KEAP1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs de stress oxydatif et des niveaux de glutathion peuvent être évalués."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour KEAP1 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests moléculaires ciblant KEAP1 peuvent être effectués pour des diagnostics précis."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction de KEAP1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress oxydatif, comme la fatigue et l'inflammation, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "La dysfonction de KEAP1 cause-t-elle des maladies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des maladies comme le cancer et les maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "On peut observer des signes d'inflammation, de douleur et de dysfonction organique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité et du type de mutation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer lié à KEAP1 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la perte de poids, la douleur et la fatigue peuvent être présents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de KEAP1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle KEAP1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à protéger KEAP1."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il KEAP1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le stress oxydatif et peut altérer KEAP1."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il KEAP1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice régulier peut réduire le stress oxydatif et soutenir KEAP1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour KEAP1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et éviter les toxines est recommandé."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent KEAP1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments antioxydants peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Les antioxydants aident-ils avec KEAP1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antioxydants peuvent réduire le stress oxydatif associé à KEAP1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour KEAP1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent des traitements ciblant les anomalies de KEAP1."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées sont-elles efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles montrent un potentiel dans le traitement des cancers liés à KEAP1."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour KEAP1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de la voie de signalisation de KEAP1 sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à KEAP1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent le cancer, les maladies respiratoires et l'inflammation chronique."
}
},
{
"@type": "Question",
"name": "KEAP1 est-il lié à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de KEAP1 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles associées à KEAP1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre KEAP1 et les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer avec KEAP1 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations de KEAP1 sont souvent associées à un risque accru de cancer."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour KEAP1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition aux toxines et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il KEAP1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dysfonction de KEAP1 augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou de cancer augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement affecte-t-il KEAP1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des polluants environnementaux peut altérer KEAP1."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un stress oxydatif accru peut contribuer à des anomalies de KEAP1."
}
}
]
}
]
}
From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
Publications dans "Protéine-1 de type kelch associée à ECH" :
From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
Publications dans "Protéine-1 de type kelch associée à ECH" :
From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
Publications dans "Protéine-1 de type kelch associée à ECH" :
From the Department of Biochemistry and Biophysics (C.M.-B., B.D.O., S.E.V., H.A.S., K.C.Z., L.M.K., J.L.D.), the Weill Institute for Neurosciences (B.T., I.O.B., S.J. Pleasure, M.R.W.), the Department of Neurology (B.T., I.O.B., S.J. Pleasure, M.R.W.), and the Chan Zuckerberg Biohub (J.L.D.), University of California, San Francisco, San Francisco; and the Departments of Laboratory Medicine and Pathology (D.D., T.J.K., A.M., V.A.L., S.J. Pittock), Neurology (D.D., A.M., V.A.L., S.J. Pittock), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Publications dans "Protéine-1 de type kelch associée à ECH" :
Oxidative stress has been implicated in a wide range of pathological conditions. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) exerts a central role in regulating the cel...
The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/Keap1) signaling pathway is involved in the regulation of cellular responses to oxidative stress. Nrf2 acts as...
In total, 90 patients with LARC underwent surgery after preoperative chemoradiotherapy (CRT). Endoscopic biopsies from the tumors were obtained before radiation, and the Nrf2 and Keap1 expressions wer...
The overexpression of the nuclear Nrf2 before CRT showed a significant correlation with better DFS. The cytoplasmic Nrf2 expression was associated with more residual tumors after radiotherapy and a mo...
CRT is an important issue in LARC and is a major aspect of treatment. Thus, the Nrf2/Keap1 expression may be a potential predictor of preoperative therapeutic resistance. The Nrf2-Keap1 modulators tha...
Elevated serum homocysteine (Hcy) level is a risk factor for Alzheimer's disease (AD) and accelerates cell aging. However, the mechanism by which Hcy induces neuronal senescence remains largely unknow...
Diabetic nephropathy (DN), a microvascular complication of diabetes, increases the risk of all-cause diabetes and cardiovascular mortalities. Moreover, oxidative stress and pyroptosis play important r...
Cadmium poisoning is mainly caused by inhalation of cadmium dust or cadmium compound dust, which greatly harms people's lives. Tea polyphenols extracted from green tea have wide biological properties,...
To explore the influences of tea polyphenols on NRF2 and KEAP1 gene expression in mice with acute cadmium poisoning....
This is an animal experiment that adopts hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) staining....
This study was carried out in Zunyi Medical and Pharmaceutical College....
Fifty specific pathogen-free (SPF) male Kunming mice aged 9 weeks, weighing 18-22 g were divided into five groups: normal group, model group, low-dose tea polyphenols group, middle-dose tea polyphenol...
Tea polyphenols were administered intraastrically into mice with doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg for 10 consecutive days, respectively....
(1) liver coefficient, (2) pathological liver injury, (3) liver function, (4) oxidative damage, and (5) NRF2 and KEAP1 gene expression....
The liver coefficient, pathological liver injury, serum aspartate transaminase and alanine transaminase levels of the model group were higher relative to the normal group (P < .05). Relative to the mo...
Tea polyphenols can relieve liver injury in mice with acute cadmium poisoning by regulating NRF2 and KEAP1 expression. Our study might provide a promising treatment strategy for acute cadmium poisonin...
Kelch-like proteins (KLHLs) are a large family of BTB-containing proteins. KLHLs function as the substrate adaptor of Cullin 3-RING ligases (CRL3) to recognize substrates. KLHLs play pivotal roles in ...
We report a case of Kelch-like protein-11 (KLHL11) encephalitis associated with squamous cell carcinoma (SCC) of unknown origin in the neck....
A 70-year-old man, diagnosed with prurigo nodularis 4 months prior, presented with subacute-onset progressive dysarthria, imbalance, and diplopia. Neurologic examination revealed horizontal and downbe...
Extensive workup for acquired brainstem syndromes revealed KLHL11 antibodies in both the serum and CSF, together with superimposed unclassified antibodies. The patient was diagnosed with KLHL11 enceph...
Our patient represents the first case of KLHL11 encephalitis associated with SCC of unknown origin in the neck, and our observations delineate a potentially novel correlation between the 2 diseases....
Anti-Kelch-like protein 11 (KLHL11) antibody encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalomyelitis associated with the presence of KLHL11 antibodies. Diagnos...
Follistatin-like protein 1 (FSTL-1) and follistatin-like protein 3 (FSTL-3) are glycoproteins whose associations with inflammatory cytokines were reported in previous studies. However, it is not yet k...
Fifty-six FMF patients and 22 healthy controls (HCs) were included in the study. Serum FSTL-1 and FSTL-3 levels were measured with the enzyme-linked immunosorbent assay method from collected serum sam...
Serum FSTL-1 levels were significantly higher in FMF patients than in HCs (p=0.005). However, there was no significant difference in FSTL-1 levels between patients in the attack period (n=26) and in t...
Our results suggest that FSTL-1 may be associated with the pathogenesis of FMF, rather than FSTL-3. However, neither serum FSTL-1 nor FSTL-3 seems to be good markers to reflect inflammatory activity....
